Robust SARS-CoV-2 antibody and T cell immunity following three COVID-19 vaccine doses in inflammatory bowel disease patients receiving anti-TNF or alternative treatments

Article Gastroenterology & Hepatology

Vaccine escape, increased breakthrough and reinfection in infliximab-treated patients with IBD during the Omicron wave of the SARS-CoV-2 pandemic

Nicholas A. Kennedy et al.

Summary: This study found that a third dose of an mRNA-based vaccine can boost antibody responses and immunity in infliximab-treated patients with IBD. However, these patients had lower antibody concentrations compared to those treated with vedolizumab and were more likely to experience breakthrough infections and reinfections.

GUT (2023)

Add to Collection

Editorial Material Gastroenterology & Hepatology

Deciphering the vedolizumab dosing conundrum in IBD: when less is more

Timon Erik Adolph et al.

GUT (2022)

Add to Collection

Article Gastroenterology & Hepatology

Humoral Immunogenicity of 3 COVID-19 Messenger RNA Vaccine Doses in Patients With Inflammatory Bowel Disease

Trevor L. Schell et al.

Summary: This study evaluated the humoral immunogenicity of a third dose of mRNA vaccine for coronavirus disease 2019 in patients with inflammatory bowel diseases. All patients showed a humoral immune response, and median antibody concentrations were higher after the third dose compared to completion of the 2-dose series.

INFLAMMATORY BOWEL DISEASES (2022)

Add to Collection

Article Immunology

Robust correlations across six SARS-CoV-2 serology assays detecting distinct antibody features

Louise C. Rowntree et al.

Summary: The study utilized various serology testing methods to conduct a comprehensive analysis of the SARS-CoV-2 virus, finding that commercial ELISA results were consistent with in-house ELISA results, rapid sVNT inhibition frequency strongly correlated with spike-specific IgG and IgA titres, and multiplex analyses revealed the strongest correlations between spike and RBD-specific antibodies.

CLINICAL & TRANSLATIONAL IMMUNOLOGY (2021)

Add to Collection

Article Multidisciplinary Sciences

Regulatory T cells suppress virus-specific antibody responses to Friend retrovirus infection

Tyler C. Moore et al.

PLOS ONE (2018)

Add to Collection

Robust SARS-CoV-2 antibody and T cell immunity following three COVID-19 vaccine doses in inflammatory bowel disease patients receiving anti-TNF or alternative treatments

Related references

Vaccine escape, increased breakthrough and reinfection in infliximab-treated patients with IBD during the Omicron wave of the SARS-CoV-2 pandemic

Deciphering the vedolizumab dosing conundrum in IBD: when less is more

Humoral Immunogenicity of 3 COVID-19 Messenger RNA Vaccine Doses in Patients With Inflammatory Bowel Disease

Robust correlations across six SARS-CoV-2 serology assays detecting distinct antibody features

Regulatory T cells suppress virus-specific antibody responses to Friend retrovirus infection

Export Citation

Share Paper